Seeking Alpha

Dendreon (DNDN)

()

News & PR
Market Currents

Buzz
Twitter: DNDN

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Mentor Capital Cancer Vaccine Investing Update

Dec 23 • Mike Havrilla • 2 Comments
30 High Yielding Option Write Ideas for November Option Expiration Friday

Nov 20 • Marco Hickey • 1 Comment
Best Performing Stocks Since 3/9/09 and 10/9/07

Nov 12 • Bespoke Investment Group • Comment!
Monday's Rx-Recap (11-02-09)

Nov 3 • M. E. Garza • Comment!
Dendreon's Provenge Looks Likely to Be Approved in Mid-2010

Nov 3 • VFC's Stock House • 8 Comments
25 Option Write Ideas for October's Expiration Friday

Oct 16 • Marco Hickey • 1 Comment
25 High-Yielding Buy-Writes for October Options Expiration

Oct 14 • Marco Hickey • 3 Comments
Dendreon: New Board Members Appointed, Things Have Never Looked Brighter

Oct 12 • VFC's Stock House • 5 Comments
Stock Watch: BDSI, ACTC.PK, ONTY

Oct 11 • VFC's Stock House • 8 Comments
OncoGenex: Room for Further Growth?

Oct 8 • EP Vantage • Comment!
Stock Watch: CPST, CVM, AGEN

Oct 6 • VFC's Stock House • 3 Comments
The Top 25

Oct 1 • Bespoke Investment Group • 1 Comment
Dendreon Investors Counting on FDA Approval of Provenge

Sep 28 • Zacks.com • 4 Comments
BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Sep 25 • Mike Havrilla • 3 Comments
Still a Lot of Potential in Dendreon and the Cancer Immunotherapy Market

Sep 25 • VFC's Stock House • 7 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers

Sep 20 • Justin M. Hall • 3 Comments
SEC Shouldn't Rest on Flash Trading Ban

Sep 18 • Matthew Goldstein • 12 Comments
Tuesday Options Recap

Sep 15 • Frederic Ruffy • 2 Comments
50 Four-Day September Expiration Option Ideas

Sep 15 • Marco Hickey • 6 Comments
Monday's Options Recap

Sep 14 • Frederic Ruffy • Comment!
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11 • Justin M. Hall • 23 Comments
Tuesday Options Recap

Aug 25 • Frederic Ruffy • Comment!
3 Reasons Not to Predict FDA Action: Matrixx, Savient, Dendreon

Aug 19 • Ruthanne Williams Roussel • 5 Comments
Market Falters but Sentiment Doesn't

Aug 18 • First Coverage • 1 Comment
As Market Drops, It's Time to Buy

Aug 18 • VFC's Stock House • 12 Comments
Stock Watch: TTNP, VNDA, DNDN, AGEN, ONTY

Aug 17 • VFC's Stock House • 3 Comments
Tracking Healthcare Trends and More

Aug 5 • Mike Havrilla • 3 Comments
Small Biopharma Ponderings

Jul 27 • VFC's Stock House • Comment!
Expected Volatility: 20 Option Straddle Ideas for High Beta Stocks

Jul 20 • Marco Hickey • 5 Comments
10 Stocks to Watch on July Options Expiration Friday

Jul 17 • Marco Hickey • 2 Comments
Russell 3,000 Stocks Up More than 200% Year to Date

Jun 28 • Bespoke Investment Group • 3 Comments
Russell Indexing Reshuffle Moves Healthcare Stocks: CXM, CTIC, HEB, CPD

Jun 26 • M. E. Garza • Comment!
A Healthy Dose of Funding for Pharma, Biotech

Jun 21 • The Burrill Report • Comment!
Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer

Jun 19 • Michael Becker • 6 Comments
Best Performing Stocks of the Last Quarter

Jun 15 • TraderMark • 4 Comments
Dendreon: Charting the Course to Big Profits

Jun 10 • Beacon Asset Managers • 15 Comments
Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships

Jun 2 • Zacks.com • 15 Comments
Biotech Stocks and the ASCO-Effect

Jun 1 • Michael Becker • 2 Comments
Russell 3000 Stocks Up 200% or More Year to Date

May 29 • Bespoke Investment Group • 2 Comments
Access Pharma: A Smallcap Cancer Biotech Call Option Trade

May 28 • Mike Havrilla • 13 Comments
A Biotech Triple Play: Dendreon, BioCryst and Arena

May 25 • Michael Murphy • 28 Comments

Dendreon (DNDN)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers